(NASDAQ: CSTL) Castle Biosciences's forecast annual revenue growth rate of 8.72% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 7.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.54%.
Castle Biosciences's revenue in 2026 is $357,278,000.On average, 11 Wall Street analysts forecast CSTL's revenue for 2026 to be $11,616,144,542, with the lowest CSTL revenue forecast at $11,102,912,824, and the highest CSTL revenue forecast at $12,003,206,795. On average, 11 Wall Street analysts forecast CSTL's revenue for 2027 to be $12,735,172,983, with the lowest CSTL revenue forecast at $11,691,907,319, and the highest CSTL revenue forecast at $13,549,317,345.
In 2028, CSTL is forecast to generate $14,071,408,419 in revenue, with the lowest revenue forecast at $12,150,760,914 and the highest revenue forecast at $15,018,137,641.